Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Recurrent CNS lymphoma continues to be associated with poor outcomes in the rituximab era. Although IV rituximab mediates superior disease control of systemic non-Hodgkin lymphoma (NHL), it fails to completely eliminate the risk of meningeal recurrence, likely due to minimal CNS penetration. Given t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rubenstein, James L., Li, Jing, Chen, Lingjing, Advani, Ranjana, Drappatz, Jan, Gerstner, Elizabeth, Batchelor, Tracy, Krouwer, Hendrikus, Hwang, James, Auerback, Glenna, Kadoch, Cigall, Lowell, Clifford, Munster, Pamela, Cha, Soonmee, Shuman, Marc A., Damon, Lloyd E.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2013
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3563362/
https://ncbi.nlm.nih.gov/pubmed/23197589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-440974
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars